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Abstract
Introduction: Microbicides were conceptualized as a product that could give women increased agency over HIV prevention.
However, gender-related norms and inequalities that place women and girls at risk of acquiring HIV are also likely to affect their
ability to use microbicides. Understanding how gendered norms and inequalities may pose obstacles to women’s microbicide use
is important to inform product design, microbicide trial implementation and eventually microbicide and other antiretroviral-based
prevention programmes. We reviewed published vaginal microbicide studies to identify gender-related factors that are likely to
affect microbicide acceptability, access and adherence. We make recommendations on product design, trial implementation,
positioning, marketing and delivery of microbicides in a way that takes into account the gender-related norms and inequalities
identified in the review.
Methods: We conducted PubMed searches for microbicide studies published in journals between 2000 and 2013. Search terms
included trial names (e.g. ‘‘MDP301’’), microbicide product names (e.g. ‘‘BufferGel’’), researchers’ names (e.g. ‘‘van der Straten’’)
and other relevant terms (e.g. ‘‘microbicide’’). We included microbicide clinical trials; surrogate studies in which a vaginal gel,
ring or diaphragm was used without an active ingredient; and hypothetical studies in which no product was used. Social and
behavioural studies implemented in conjunction with clinical trials and surrogate studies were also included. Although we
recognize the importance of rectal microbicides to women, we did not include studies of rectal microbicides, as most of them
focused on men who have sex with men. Using a standardized review template, three reviewers read the articles and looked for
gender-related findings in key domains (e.g. product acceptability, sexual pleasure, partner communication, microbicide access
and adherence).
Results and discussion: The gendered norms, roles and relations that will likely affect women’s ability to access and use
microbicides are related to two broad categories: norms regulating women’s and men’s sexuality and power dynamics within
intimate relationships. Though norms about women’s and men’s sexuality vary among cultural contexts, women’s sexual
behaviour and pleasure are typically less socially acceptable and more restricted than men’s. These norms drive the need for
woman-initiated HIV prevention, but also have implications for microbicide acceptability and how they are likely to be used by
women of different ages and relationship types. Women’s limited power to negotiate the circumstances of their intimate
relationships and sex lives will impact their ability to access and use microbicides. Men’s role in women’s effective microbicide use
can range from opposition to non-interference to active support.
Conclusions: Identifying an effective microbicide that women can use consistently is vital to the future of HIV prevention for
women. Once such a microbicide is identified and licensed, positioning, marketing and delivering microbicides in a way that
takes into account the gendered norms and inequalities we have identified would help maximize access and adherence. It also
has the potential to improve communication about sexuality, strengthen relationships between women and men and increase
women’s agency over their bodies and their health.
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Introduction
HIV is the leading cause of death among women of repro-
ductive age worldwide [1], and the incidence of HIV among
women has been rising for more than a decade [2]. Women’s
HIV risk is driven in large part by gendered norms and
structural inequalities between women and men.
In the majority of societies, men are economically and
socially dominant over women, with social norms often
justifying this arrangement as ‘‘natural.’’ Despite global
patterns of inequality, gendered roles, norms and relations are
manifested differently in different regions and change over
time. Gendered social norms and power dynamics between
women and men are influenced by global and local histories,
economies and values. In many contexts, prevalent constructs
of masculinity pressure men and boys to control sexual
decision-making, have multiple partners and aggressively
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pursue sex  sometimes to the point of coercion [3]. Women
are often expected to be submissive on sexual matters, hin-
dering their ability to negotiate safer sex practices, especially
in the context of marriage, violent relationships and inter-
generational partnerships [3,4]. This social system also limits
women and girls’ access to education, autonomous livelihoods
and financial resources, which leads some to engage in
transactional sex. Intimate partner violence (IPV) is perva-
sive in many countries [5] and is another key factor driving
women’s HIV vulnerability. Traditional HIV prevention ap-
proaches remain dependent onmale initiation or cooperation,
exacerbating women’s vulnerability to HIV when they are
unable to influence their partner’s commitment to monogamy
or to negotiate condom use.
Vaginal microbicides are products conceptualized in the
early 1990s to give women increased control and agency over
HIV prevention [6]. Together with oral pre-exposure prophy-
laxis (PrEP), these antiretroviral (ARV) drug-based products
could create an HIV prevention landscape where women have
choices of different formulations of HIV prevention products
that they can initiate and use with or without their partners’
agreement. The CAPRISA 004 study provided proof of concept
that vaginal 1% tenofovir gel reduces HIV infections by
39 percent in women and genital herpes infections by 51%
[7]. However, the subsequent VOICE and FACTS 001 trials
were not able to confirm the effectiveness of microbicide gels,
largely due to low adherence to the gel, especially by younger
women, many of whom were in unstable partnerships and/or
living with their parents [8,9].
The issue of adherence is complex and likely driven by
beliefs about the product’s efficacy and perception of one’s
own risk, both of which may vary among women of different
ages, relationship status and economic circumstances. For
example a married woman may be more inclined to go
against her husband’s wishes to use a product that is 90%
effective than one that is only 30% effective, and a woman
may be more likely to adhere to a product if she knows her
partner is HIV positive. However, in some contexts women
are less likely to know their partner’s HIV status than men
[10]. These are just a few of the gendered norms that can
affect women’s motivations, willingness and ability to adhere
to a gel regimen.
The future of microbicide gel is uncertain, but the results
of the FACTS 001 and VOICE trials underscore the need for
continued research into HIV prevention options that work
for women. Similarly, FEM-PrEP and VOICE were not able to
demonstrate the effectiveness of oral PrEP among women.
We are still learning what works for women in different
circumstances. The CAPRISA 008 study, an open-label study
testing the use of 1% tenofovir gel accessed in family planning
clinics may give us more insight into how well women adhere
to gel when they know the product is effective. Additionally,
we are awaiting results from trials testing delivery of ARV
drugs through vaginal rings worn continuously and changed
monthly. Regardless of the direction the ARV-based HIV pre-
vention field takes, we can learn a great deal from examining
gender issues raised in social and behavioural studies of vagi-
nal microbicides, as these same gender dynamics will likely
affect the acceptability and use of other woman-initiated HIV-
prevention products. This review aims to identify gender
norms that are likely to facilitate or pose barriers to women’s
access to and use of ARV-based prevention products outside
of the trial context.
Methods
We conducted PubMed searches for microbicide studies
published in journals between 2000 and 2013. Search terms
included trial names (e.g. ‘‘MDP301’’), microbicide product
names (e.g. ‘‘BufferGel’’), researchers’ names (e.g. ‘‘van der
Straten’’) and other relevant terms (e.g. ‘‘microbicide’’). We
included microbicide clinical trials; surrogate studies in which
a vaginal gel, ring or diaphragm was used without an active
ingredient; and hypothetical studies in which no product was
used. Social and behavioural studies implemented in conju-
nction with clinical trials and surrogate studies were also
included. Although we recognize the importance of rectal
microbicides to women, we did not include studies of rectal
microbicides, as most of them focused on men who have
sex with men. Using a standardized review template, three
reviewers read the articles and looked for gender-related
findings in key domains (e.g. product acceptability, sexual
pleasure, partner communication, microbicide access and
adherence).
We anticipated differences in the gender issues based on
the type of study because womenwho participate in surrogate
studies or clinical trials actually experience the challenges
of using a product while women in hypothetical studies can
only imagine the issues they may face. We also anticipated
differences among geographical regions, study population or
product formulation. However, we found the gender-related
results to be surprisingly similar across study types, products,
populations and locations. Any notable differences, as well as
instances where data comes primarily from one study type,
are detailed in the findings. Additionally, Tables 1 through
3 present the included studies by study type, product, popu-
lation and location.
After presenting the results from the literature review,
we discuss the implications for future microbicide research
and potential microbicide introduction, including marketing,
service delivery, counselling and support for women and
community education. We also explore potential effects of
microbicide introduction on women’s empowerment and
gender relations.
Results and discussion
The gender norms, roles and relations that will likely affect
women’s ability to access and use microbicides fall into two
broad categories: 1) norms related to women’s and men’s
sexuality and 2) power dynamics within intimate relation-
ships. We also discuss the ways in which microbicide intro-
duction may affect the relative status of women and men.
Norms related to women’s and men’s sexuality
Though norms about women’s andmen’s sexuality vary among
cultural contexts, women’s sexual behaviour and pleasure
are typically less socially acceptable and more restricted than
men’s [1114]. For example, in many contexts, including parts
Doggett EG et al. Journal of the International AIDS Society 2015, 18:20536
http://www.jiasociety.org/index.php/jias/article/view/20536 | http://dx.doi.org/10.7448/IAS.18.1.20536
2
Table 1. Hypothetical studies
Reference/reference number Hypothetical product Countries Study population Method
Becker [71] Not specified South Africa 38 IDIs; 23 FGDs with women and men Qual
Bisika [34] Gel Malawi 32 women; 55 men Qual
Coggins [26] Gel Mexico, USA, Zimbabwe 90 men Qual
Hammett [75] Gel USA, Puerto Rico 743 women Quant
Hoel [25] Not specified South Africa 29 women Qual
Kohli [16] Gel India 15 men Qual
Lees [23] Gel Tanzania Ethnographic observation of 1573
women; approximately 20 men. Six FGDs
with women; two with men; 812
participants in each group
Qual
Montandon [56] Gel Kenya 30 adolescent girls plus some 31
mothers and community leaders;
28 fathers and community leaders
Qual
Ramjee [70] Gel South Africa 243 men Qual
Terris-Prestholt [81] Gel South Africa 22 women Mixed
Orner [17] Gel South Africa 213 women Qual
Tolley [60] Gel India 30 women; 15 men Qual
van der Straten [54] Diaphragm Zimbabwe 75 women Quant
van de Wijgert [27] Gel Zimbabwe 43 men Qual
Veldhuijzen [35] Gel Rwanda Seven FGDs with approximately
80 women and men
Qual
Woodsong [72] Topical microbicides India, Malawi, South Africa,
Tanzania, Zambia, Zimbabwe, USA
Not specified (review of three studies) Qual
IDI, In-Depth Interview; FGD, Focus Group Discussion; Qual, Qualitative; Quant, Quantitative.
Table 2. Surrogate studies
Reference/reference
number Surrogate product Countries Study population Method
Green [59] Female condom, foaming tablets,
contraceptive sponge, Delfen foam,
film and gel
Uganda 131 women; 21 men Qual
Jones [33] Astroglide Silken Secret (high-viscosity
gel), KY Jelly (low-viscosity gel),
Lubrin (suppository)
Zambia 301 women Quant
Martin [15] Gel Thailand 23 women; 28 men Qual
Montgomery [20] Gel South Africa, Tanzania,
Uganda, Zambia
45 couples Qual
Pool [48] Female condom, foaming tablets,
contraceptive sponge, Delfen foam,
film and gel
Uganda 138 women; 42 men Qual
Salter [43] Gel Malawi 1686 women; 21 men Mixed
Tanner [21] Silken Secret vaginal moisturizer USA 40 women Qual
van der Straten [61] Ring South Africa, Tanzania 157 women; 19 men Qual
Weeks [74] Vaginal moisturizer USA 546 women interviewed/surveyed;
94 participating in surrogate trial
Mixed
Qual, Qualitative; Quant, Quantitative.
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Table 3. Microbicide clinical trials
Reference/reference
number Product Countries Study participants Method
Abaasa [58] Gel Uganda 544 women Quant
Abdool Karim [7] Gel South Africa 889 women Quant
Behets [57] Gel; diaphragm with gel Madagascar 314 women Quant
Bentley [28] Gel Zimbabwe, Malawi, India, Thailand 99 women and men Mixed
Carballo-Dieguez [36] Gel USA 21 men Mixed
Carballo-Dieguez [24] Gel USA, Puerto Rico 69 women Mixed
Gafos [12] Gel South Africa 136 women; 61 men Qual
Gafos [37] Gel South Africa 34 women Qual
Gafos [69] Gel South Africa 1092 women Mixed
El Sadr [46] Gel USA 59 women; 11 men Quant
Greene [38] Gel Uganda, Benin and India 53 women Qual
Guest [18] Diaphragm with gel South Africa 120 women Mixed
Hoffman [41] Gel USA 79 women Qual
Kacanek [19] Diaphragm with gel South Africa, Zimbabwe 206 women; 41 men Qual
Kacanek [76] Diaphragm with gel South Africa, Zimbabwe 4505 women Quant
Lanham [62] Gel, ring South Africa, Kenya, Tanzania 535 interviews, 107 focus groups with men
and women
Qual
Marrazzo [8] Gel and oral PrEP South Africa, Uganda, Zimbabwe 5029 women Quant
Mantell [39] Gel South Africa 94 women Qual
Mngadi [65] Gel South Africa 846 women Quant
Montgomery [14] Gel South Africa, Zambia, Tanzania and
Uganda
464 women Qual
Montgomery [64] Gel Zimbabwe, South Africa 2452 women Quant
Montgomery [31] Diaphragm with gel Zimbabwe 103 women Quant
Montgomery [32] Diaphragm with gel Zimbabwe 955 women Quant
Muchomba [67] Oral PrEP, gel Multicountry; not specified 47,157 women and men Quant
Mzimela [50] Gel South Africa 33 women and men Qual
Pistorius [40] Gel South Africa 64 women Qual
Ramjee [22] Gel South Africa 40 women; 37 men Mixed
Ramjee [44] Gel South Africa 40 women; 20 men Mixed
Rosen [41] Gel USA 79 women Mixed
Sahin-Hodoglugil [66] Diaphragm with gel South Africa and Zimbabwe 2316 women surveyed, 104 in FGDs;
37 men
Mixed
Sahin-Hodoglugil [30] Diaphragm with gel Zimbabwe and South Africa 105 women; 41 men Qual
Stadler [45] Gel South Africa 179 women (42 FGDs with women trial
participants and community members);
42 men (42 FGDs with women trial
participants and community members)
Qual
Stadler [49] Gel South Africa 150 women Mixed
Vandebosch [73] Gel Coˆte d’Ivoire; Benin; South Africa;
Thailand
764 women Quant
van der Straten [63] Diaphragm with gel Zimbabwe 117 women Quant
Venables [42] Gel South Africa 175 women; 82 men Mixed
Whitehead [68] Gel Thailand 271 women Quant
Woodsong [13] Gel Malawi 321 women (81 community stakeholders
and health providers);
109 men (81 community stakeholders and
health providers)
Qual
PrEP, pre-exposure prophylaxis; FGD, Focus Group Discussion; Qual, Qualitative; Quant, Quantitative.
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of sub-Saharan Africa and Southeast Asiawhere themajority of
the microbicides studies have been conducted, women are
expected to be virgins before marriage and monogamous
within marriage. In contrast, it is often accepted as inevitable
and even considered masculine for men to have multiple
partners regardless of marital status [1519]. Similarly,
women  especially young women  are expected to be naive
and passive in relation to sexuality [11], which impacts
women’s negotiation of the frequency and safety of sex, as
well as their experience of sexual pleasure. Thus, sexual norms
related to women’s age, relationship or marital status, sexual
pleasure and other sexual preferences and practices, such
as so-called dry sex, affect the acceptability and use of
microbicides, including perceptions of who is an appropriate
microbicide user.
Sexual norms, risk perception and microbicide user groups
In microbicide trials and hypothetical studies, women’s,
men’s and couples’ opinions were mixed about which women
are most at risk, which influences both perceptions of the
appropriate user group for microbicides as well as adherence
to microbicides. In several studies, women in steady partner-
ships, including married women, were perceived to benefit
most from microbicides [1522], because so many married
women have limited control over negotiating sex and con-
dom use [1519,23]. As discussed below, this difficulty stems
in part from issues of trust and intimacy within primary or
married relationships. In other studies, married women were
not perceived to be at risk for HIV and therefore microbicides
were viewed as unnecessary within marriage [15,24,25]. In
these studies, respondents felt that sex workers, women with
casual sex partners or women in HIV serodiscordant relation-
ships were the most appropriate user groups for microbicides
[1517,2628]. However, respondents in one microbicide
surrogate study predicted that if microbicides are promoted
only to specific high-risk groups such as female sex workers,
the product could be perceived to be linked to infidelity and
risky behaviours [20], potentially stigmatizing microbicides
and precluding married women and adolescents from using
them.
In addition to product acceptability, we know from the
oral PrEP literature that risk perception is positively asso-
ciated with product adherence [29]. Unfortunately, due to
the gendered sexual expectations discussed above, many
women’s primary risk is via their main or stable partner.
Because women may be less likely than men to know their
partner’s status, it can be difficult for women to estimate
their risk accurately [10].
Sexual pleasure
The potential for promoting sexual pleasure  for women
and men alike  is a distinct advantage of vaginal microbicide
products. Sexual pleasure is highly gendered, such that men’s
pleasure often takes precedence over women’s pleasure
[13,21,3032]. This disparity has implications for how micro-
bicides are marketed and for whether people will choose to
replace condoms with microbicides or use the two methods
together.
Increased sexual pleasure from the additional lubrica-
tion in gel formulations and increased libido from product
use positively influenced the acceptability of microbicides
[13,3335]. Most microbicide trials found that the gel
increased sexual pleasure [15,16,18,24,28,30,3645] or at least
did not change sexual pleasure [24,28,41,46,47]. This finding
was true across study populations  including sex workers,
women and men with steady partners and HIV-positive and
HIV-negative people. It should be noted that, though accept-
ability was sometimes influenced by both female and male
sexual pleasure [12,14,37,48], a stronger predictor of accept-
ability in some studies was a male partner’s sexual pleasure,
and women’s experiences of sexual pleasure often referred
to lack of pain during coitus or to pleasuring their partner
[13,21,3032]. In a study from South Africa, some women
reported that they touted the potential for increased sexual
pleasure in order to convince their partners to agree to their
use of the product and to reduce the likelihood of their
partners’ negative or violent reactions [49].
Many HIV prevention experts have expressed concern that
the introduction of microbicides might further discourage
people from using condoms, which offer greater HIV protec-
tion on a per-sex-act basis, added protection from other STIs
and pregnancy and are likely less expensive than microbicides.
Indeed, some women and men in trials, surrogate studies and
hypothetical studies felt that a microbicide gel was preferable
to condoms because of the greater sexual pleasure it offers
[15,16,41,44,45]. In other studies in which both gel and con-
doms were used, some female and male participants indi-
cated that the increased sexual pleasure offered by the gel
balanced the decreased sexual pleasure experienced with
condom use and hence enabled both condoms and gel to be
used simultaneously [18,37,41,50]. Furthermore, consistent
microbicide use may provide a woman more HIV protection
over time than inconsistent condom use. Evidence suggests
that the decision to use condoms is dominated by men, and
it is not clear what impact the availability of an effective
microbicide will have on the power dynamics and decision-
making related to condom use [51,52]. Public health experts
have discussed the possibility of promoting microbicides for
use in relationships or individual sex acts where women are
unable to negotiate condom use.
Sexual preferences and related intravaginal practices
The perception that men often prefer what is termed ‘‘dry’’
or ‘‘tight’’ sex also has implications for microbicide accept-
ability. However, the term dry is likely a misnomer: a
multicountry study found that practices to enhance sexual
pleasure ‘‘are not always aimed at ‘drying’ the vagina, but
rather at ‘closing, warming and tightening’ the vagina’’ [53].
In some studies where dry sex was the stated preference,
women feared that men would not like the added lubrication
from a microbicide gel [13,34]. Because vaginal wetness is
often linked to accusations of sexual promiscuity, infidelity
or masturbation, there is a risk that lubrication from the
microbicide gel could lead to accusations of impropriety
[16,20,34,36] and even end a relationship [26].
However, for the most part, these fears were not realized
among microbicide users. Two clinical trials in South Africa
and Malawi found that women and men enjoyed the gel’s
lubrication, even among a minority of women who were initially
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concerned about the gel increasing vaginal wetness [12,13].
Other trials and surrogate studies in Malawi, South Africa,
Zambia, Tanzania and Uganda found that the use of vaginal
gels resulted in gains in sexual pleasure that were previously
sought from other types of intravaginal insertions [12,14,43,
45,54]. One surrogate gel study in Tanzania was an exception
in that some men disliked the added lubrication and this
influenced product use [20].
Women who have experience with vaginal insertion,
usually in the form of inserting herbs and other products
into the vagina to promote pleasure  in particular men’s
pleasure  during sex [55] could find microbicide use easier
and more acceptable, in comparison with women who are
inexperienced with vaginal insertion [56].
Women’s power within intimate relationships
Women’s power to negotiate the circumstances of sex will
impact their ability to access and use microbicides. This in-
cludes practical matters like women’s lack of control over
the timing of sex or the privacy to store and insert the gel,
the dilemma of whether to discuss use of microbicides with
male partners and the risk of experiencing IPV when using
microbicides. Moreover, men’s role in women’s effective micro-
bicide use can range from opposition to non-interference to
active support.
Power to control timing of sex and privacy
In many areas, men are the primary decision-makers about
sexuality; thus, women cannot always control or predict the
circumstances of their sex lives. Women participating in
microbicide trials, their male partners and people intervie-
wed about potential microbicide use in Benin, India, Malawi,
South Africa, Thailand, Uganda, the United States and
Zimbabwe noted that women’s lack of privacy to insert the
gel [16,28,38,44,57,58] and limited ability to control the
timing of sex (and thus the ability to apply the gel before sex)
[13,34,38,41,44,59,60] may interfere with women’s adher-
ence to a coitally dependent microbicide regimen. A hypo-
thetical study among adolescent girls, their parents and other
community leaders in Kenya found the timing of gel insertion
would likely be a challenge among adolescent girls, whose
sex lives were described as unpredictable, rushed and illicit
[56]. A ring formulation may pose fewer challenges related to
privacy and timing of sex, since the ring can remain in the
vagina for a month after it is inserted. Indeed, participants in a
placebo ring study in South Africa and Tanzania reported
discreetness, convenience and being able to leave the ring in
for four weeks as favourable attributes of this product [61].
Male partner engagement and communication
Male partners and partnership dynamics will likely play a
major role in microbicide acceptability and women’s ability
to use a gel product regimen [62]. In trials and surrogate
studies, women’s willingness to use microbicides and ability
to adhere to product regimens were often influenced by
women’s perceptions of their partner’s acceptance of the
products [31,32,43,45,6366]. It should be noted that men’s
involvement in microbicide use can range from constructive
to coercive. Female and male respondents in trials, surro-
gate studies and hypothetical studies found that some men
supported adherence in a constructive way, for example by
reminding their partners to use the gel or helping them
to insert it [14,20,32,38,40,62,64], whereas others were
more coercive, demanding that their partners use the gel
[20,40,62].
Women’s ability to use microbicides will likely vary in differ-
ent kinds of relationships. A literature review of 14microbicide
trials found that one of the most frequently cited reasons
for non-adherence was having sex with steady partners as
opposed to casual or paying partners [67]. Likewise, trial
participants in Benin, Uganda and India  many of whom
were involved in sex work  reported that adherence to
the gel regimen was easier with casual partners than with
steady partners [38]. These differences are likely linked
with trust issues within intimate relationships, as well as
women’s sexual negotiating power, a factor found to be
associated with consistent gel use in a microbicide gel safety
trial in India [60].
A key characteristic of microbicides is that women may be
able to use them without their partners’ knowledge. Studies
have confirmed that women value having a product they can
use without communicating with their partner [19,38,41,46
48,61,64,68]. However, study findings also suggest that many
women will likely talk with their partners about using micro-
bicides. In all clinical trials and surrogate studies that asked
about partner communication, participants typically talked
with steady partners about their microbicide use at some
point during study participation [12,14,30,32,37,42,61,66,69].
Relationship type also affects whether and how women
communicatewith their partners aboutmicrobicide use.Women
and men in steady relationships preferred joint decision-making
on microbicide use [15,20,25,26,28,36,44,47,60,66,7072]. In
steady relationships, using microbicides without partner com-
munication may imply infidelity or mistrust [15,35,61,66] or be
perceived as challenging male authority and decision-making
[16,72]. Useof amicrobicide gelwithout partner communication
may be more acceptable and feasible in casual or new partner-
ships, in which perceived HIV risk is likely to be highest
[13,35,36,41,73]. Using a microbicide without a partner’s
knowledge was more common among trial participants in
casual relationships and sex workers [38,66]. Women noted
that a change in the amount of lubrication from the gel may be
more noticeable to a steady partner than to a casual partner
[12,15,20,36,38,47]. Nonetheless, many women and men in
trials and hypothetical studies in sub-Saharan Africa, and in
particular South Africa, acknowledged the reality that some
women in steady partnerships, including married women,
were likely to use the product without telling their partners
[13,17,25,44].
A woman’s decision to communicate with her partner
about microbicides may differ by product formulation. Most
of the evidence regarding partner communication about
microbicides comes from gel trials; a woman may feel less of
a need to discuss use of a microbicide ring or injectable with
her partner because these products may be less noticeable
to the partner. More evidence is needed about whether and
how women communicate with their partners about micro-
bicide rings and injectables. Finally, though the literature
has not discussed women’s negotiating power in relation to
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levels of product efficacy, the efficacy of a product is also
likely to influence whether and how a woman discusses the
product with her partner as well as her negotiating power if
she does decide to discuss it.
Intimate partner violence
The perpetration of violence against women by intimate
partners is pervasive around the world and is a major
contributor to ill health  including HIV  among women [5].
Although particular attention needs to be paid to the role
of violence in women’s lives, the literature has not explored
the effect of violence on women’s microbicide use in much
depth. Some women may fear or experience violent reac-
tions from their partners if they bring up the subject of
microbicides or use microbicides without their partners’
knowledge. IPV may also affect women’s microbicide ad-
herence and the likelihood of substituting microbicides for
condoms, though the specific dynamics of these relationships
are not well understood.
About 40 percent of women participating in in-depth
interviews at one gel trial centre in South Africa reported
experiencing IPV during the trial. More than half of the
violent episodes were related to the woman’s trial participa-
tion, specifically partners’ dissatisfaction with the gel and
disapproval of trial participation and trial procedures, includ-
ing required condom use [49]. In surrogate studies, women’s
willingness to use microbicides was negatively influenced by
a history of male violence [74,75].
Deciding whether to talk to a partner about microbicide
use may be more complicated for women in violent or
abusive relationships. If a woman tries to use a gel product
without her partner’s knowledge and her partner finds out,
he may react violently [13,30,61,69,71]. Some women may
decide to communicate with their partner about microbicide
use because they fear a negative or violent reaction if their
partner discovers they have been using a product without
discussing it first [20,69].
It also seems that some women in abusive relationships
find condom use and microbicide adherence more challen-
ging. Sex workers in Thailand reported that gel adherence
was more difficult with violent clients [38]. Similarly, experi-
ence of partner violence among women in a diaphragm trial in
South Africa and Zimbabwe was closely associated with non-
adherence to both condoms and the diaphragm [76]. Finally,
a trial of diaphragms with microbicides in Zimbabwe found
that women who experienced domestic violence were more
likely to substitute diaphragms with microbicides for condoms
than women who had not [63].
Microbicides and women’s status
Though microbicides themselves will not empower women,
microbicide introduction has the potential to increase
women’s control over their health and sexuality and to be
a vehicle for promoting couples’ communication and improv-
ing their relationships. For example, several gel trials and
one surrogate gel study found that partner communication
about microbicide use can have a range of benefits including
increased communication about sex, increased pleasure and
intimacy, improved relationship dynamics, shared responsi-
bility for protection and increased self-reported microbicide
adherence [20,38,40,42]. Even though gendered relation-
ship dynamics often put women at a disadvantage overall in
negotiating HIV protection, in-depth interviews with women
revealed that many are highly resourceful in managing
relationship dynamics and often find creative ways to justify
microbicide use [69]. Likewise, some women participating
in surrogate studies expressed that having ownership of the
product and information about it gave them some degree of
power in negotiating microbicide gel use [20,21,59]. A trial of
a diaphragm with gel in South Africa and Zimbabwe and a gel
trial in South Africa found that although many trial partici-
pants decided to discuss microbicides with their partner
initially, in many circumstances ongoing use was the woman’s
decision [66].
Implications for future research and product introduction
Understanding how gendered roles and norms play into
women’s ability to use vaginal microbicides is critical to
advancing research and informing the introduction of a range
of woman-initiated HIV prevention products. We know that
gender inequality impacts all women, but not every woman
experiences gender inequality in the same ways, especially in
different life stages, relationships and other circumstances.
Ultimately, women need an array of products to choose from,
guidance on matching their needs with a product and sup-
port for optimizing the protection a product offers. The
findings from our review offer insights for product design,
specifically which types of products may work best for
women in different circumstances. They also should inform
future trials of ARV-based prevention methods, including
how to provide adherence counselling for women and how
to engage male partners. As woman-initiated HIV prevention
products make their way to markets, these findings can help
policy makers and programme designers position and deliver
the products in ways that maximize access, adherence and
more realistic risk perception. They also suggest ways to
leverage product introduction to promote open communica-
tion about sexuality, improve relationships between women
and men and increase women’s agency over their bodies and
health.
Given the low adherence to study product in the VOICE
and FACTS 001 trials, we need to better develop and match
women with products that they can use successfully. For
example, young women might have difficulties with a coitally
dependent method like a vaginal gel because their sexual
relationships may be unpredictable or because they lack the
privacy to insert a product before sex; they may be more able
to adhere to a longer-acting product like a ring or injectable
product. On the other hand, a coitally dependent gel might
be ideal for older or married women who are better able to
predict when they will have sexual intercourse, who may be
more likely to discuss and make decisions about microbicide
use together with their partners or who may appreciate the
lubricating qualities of the gel.
Microbicide acceptability could be promoted in clinical
trials and potential product rollout by 1) acknowledging that
many women  including married women and adolescent
women  are at risk of HIV, but also being culturally sensi-
tive to fears about infidelity and trust; and 2) engaging
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communities  including men  to raise awareness about
and broad acceptance of the product and its value to women
and families in the community.
Social norms around female sexuality that encourage
women to remain naive about sex and submit to male autho-
rity in sexual encounters are even more pronounced among
young women. Many young women have limited power to
enforce sexual consent and to negotiate safety and pleasure.
The same issues hinder parents’ and healthcare providers’
acceptance of adolescent girls’ sexuality and need for infor-
mation and HIV protection. Moreover, developmentally ado-
lescents may have difficulties accurately assessing their risk
[77], planning ahead or controlling impulses. Results from
FACTS 001 and VOICE showed that young women had more
challenges with adherence than older women, especially when
they did not have a single/primary partner andwhen they lived
with their parents [78]. In these situations, women often lack
privacy and the ability to anticipate when they will have sex.
Although adolescent girls are a key population at high risk of
acquiring HIV infection in many settings, fewmicrobicide trials
have included adolescents. The FACTS 002 trial, which will test
the safety and acceptability of tenofovir gel among adolescent
women in South Africa, will contribute more evidence in this
area [79]. Additional research with adolescent girls  including
enrolling them in trials and demonstration projects  is needed
to ensure ARV-based HIV prevention products are acceptable
and easy to use among adolescents.
As with other health services and commodities  like
condoms and contraception  gender inequality is also likely
to limit women’s access to an ARV-based prevention product.
The CAPRISA 008 study will simulate more ‘‘real world’’
delivery of microbicides and help identify barriers womenmay
face to accessing the product in public-sector facilities [80].
Integrating microbicides or other woman-initiated prevention
products into services women already attend, such as family
planning and prenatal care, may increase access. Adolescents
may prefer to access products through other youth-friendly
services, if they are available. Given some women’s limited
access to resources, ARV-based prevention products will also
need to be affordable  either heavily subsidized or free  so
that cost does not create a major barrier to access.
A microbicide programme will also need to recognize and
address complex gendered norms and practices in relation
to sexual pleasure and traditional intravaginal practices. For
example, including marketing messages about microbicides’
potential for increased sexual pleasure as part of a broader
marketing strategy may make the product appealing to many.
However, this strategy is unlikely to be optimal in all settings
given that women’s sexual pleasure is still taboo in some
contexts [81]. Programme designers should use such market-
ing strategies only when culturally appropriate and pretest
all marketing messages. Finally, marketing messages about
sexual pleasure should strive to be sex-positive and carefully
challenge social norms that prioritize male sexual pleasure
and condemn female sexual pleasure.
Although it may not be realistic to expect widespread dual
use of microbicides and condoms, we need to ensure that
women who already are successfully negotiating condom
use do not lose their ability to do so with the availability of
other HIV prevention products. Gendered norms that affect
how feasible it is for a woman to insist on condom use may
vary over the course of a woman’s life and in different
relationships, and in fact women’s experiences in microbicide
trials have highlighted the creativity that women can bring to
managing everyday relationship dynamics. Woman-initiated
prevention products could be promoted for use by women in
contexts where they are not able to negotiate condom use,
such as within marriage and other long-term partnerships,
while continuing to promote condoms in casual relationships
and for transactional or paid sex. On an individual level, pro-
viders can help women and couples determine the most
appropriate HIV prevention method for their situations,
keeping in mind that microbicides are likely to be less effec-
tive than condoms but, if used consistently, are likely to pro-
vide more HIV protection than inconsistent condom use [82].
A woman’s decision about whether and how to commu-
nicate about microbicides is complex. We need to deter-
mine how to support a woman in this decision in a way
that promotes greater self-determination, improves couples’
communication and anticipates any negative consequences a
woman might experience from her partner. Counselling can
help women strategize about how to talk with their partners
if they want to and what to do if a woman’s partner discovers
she has been using microbicides or another prevention
method without his knowledge. Further, microbicide trials
and eventually microbicide programmes should consider how
to constructively engage men so they can support  or at
least not actively impede  their partners’ product use when
such support is desired by the woman. Promoting men’s
awareness of woman-initiated HIV-prevention products through
community education could make it easier for couples to
discuss the methods. However, recognizing that women have
varying levels of power in relationships, strategies to engage
men in product introduction must also be careful not to
undermine a woman’s autonomy to decide whether to use the
product and whether to communicate with her partner about
it [62]. Some trials are already counselling women about
partner communication and working to engage men, but
evaluation is needed to determine which approaches pro-
mote microbicide adherence, improve relationship quality
and produce gains toward gender equality.
Few sexual health services adequately assess women’s
risk of IPV, but the introduction of microbicides could offer
the potential to better coordinate efforts to address IPV
while offering women new tools to mitigate the risk of HIV.
As such, when basic services for survivors of IPV are avail-
able, healthcare providers should proactively screen for IPV,
counsel women and make referrals to support services.
Providers will also need to be prepared to address the
potential effect of IPV on adherence and a woman’s decision
about whether to talk with her partner about product use.
Knowledge gaps remain about how woman-initiated HIV
prevention products will affect women’s status, empower-
ment and relationship dynamics. Given the influence of
gendered norms on microbicide acceptability and adherence,
future trials and programmes should measure the impact of
product introduction on gender-related outcomes. Measurable
outcomes could include women’s increased knowledge of
Doggett EG et al. Journal of the International AIDS Society 2015, 18:20536
http://www.jiasociety.org/index.php/jias/article/view/20536 | http://dx.doi.org/10.7448/IAS.18.1.20536
8
sexuality and HIV protection, increased couples’ communica-
tion and more gender-equitable attitudes among microbicide
users and their partners. Programmes may also want to
monitor whether microbicide use or negotiation triggers vio-
lent episodes, especially among women who live in situations
of ongoing abuse  and if so, whether the health system
effectively supports these women. Further research is neces-
sary to understand whether, in the context of an effective
product, couples will make decisions together about HIV
prevention or if the burden of responsibility for HIV pre-
vention will shift to women. Moreover, in designing pro-
grammes to mitigate the gender inequalities highlighted
in this paper, it is important not to reinforce notions of
women’s unequal status and disempowerment.
Conclusions
Microbicides and other ARV-based products are not a magic
bullet for HIV prevention or women’s empowerment. Whereas
identifying effective woman-initiated products will offer an
important way for women to protect themselves from HIV, such
products will fall short of their potential if gender norms are not
taken into account when testing and introducing new technol-
ogies. This review illustrates that gender norms will likely affect
many aspects of use of woman-initiated HIV prevention pro-
ducts, including the degree to which they are seen as necessary
and acceptable for women to use; whether women who
want microbicides or other products can easily access them;
whether and how women will communicate with their partners
about product use and how men will respond; and how well
women will adhere to the dosing regimen. However, if product
introduction programmes include strategies to overcome the
gender-based obstacles women may face, the programmes will
have the potential to increase couples’communication, improve
relationship quality, reduce women’s HIV risk, give women
increased knowledge about sexuality and enhance women’s
power to prevent HIV.
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